GB201515387D0 - Compositions - Google Patents

Compositions

Info

Publication number
GB201515387D0
GB201515387D0 GBGB1515387.7A GB201515387A GB201515387D0 GB 201515387 D0 GB201515387 D0 GB 201515387D0 GB 201515387 A GB201515387 A GB 201515387A GB 201515387 D0 GB201515387 D0 GB 201515387D0
Authority
GB
United Kingdom
Prior art keywords
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1515387.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazentis SA
Original Assignee
Amazentis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazentis SA filed Critical Amazentis SA
Priority to GBGB1515387.7A priority Critical patent/GB201515387D0/en
Publication of GB201515387D0 publication Critical patent/GB201515387D0/en
Priority to EP16757263.5A priority patent/EP3340977B1/en
Priority to KR1020187007291A priority patent/KR102660005B1/ko
Priority to CN201680050456.6A priority patent/CN108289879B/zh
Priority to US15/757,293 priority patent/US10695320B2/en
Priority to PCT/EP2016/070255 priority patent/WO2017036992A1/en
Priority to MX2018002543A priority patent/MX2018002543A/es
Priority to PT167572635T priority patent/PT3340977T/pt
Priority to CA2996724A priority patent/CA2996724C/en
Priority to HK18116292.1A priority patent/HK1257500B/en
Priority to SG10202001793PA priority patent/SG10202001793PA/en
Priority to JP2018529732A priority patent/JP7227003B2/ja
Priority to AU2016314987A priority patent/AU2016314987B2/en
Priority to ES16757263T priority patent/ES2936723T3/es
Priority to BR112018003745-1A priority patent/BR112018003745B1/pt
Priority to KR1020247012842A priority patent/KR102822365B1/ko
Priority to RU2018108136A priority patent/RU2754761C2/ru
Priority to US16/901,182 priority patent/US11337957B2/en
Priority to US17/737,605 priority patent/US11925616B2/en
Priority to JP2022144671A priority patent/JP2022177130A/ja
Priority to US18/417,794 priority patent/US20240148690A1/en
Priority to JP2024174863A priority patent/JP2025004129A/ja
Priority to US19/310,137 priority patent/US20260216125A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1515387.7A 2015-08-28 2015-08-28 Compositions Ceased GB201515387D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB1515387.7A GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions
RU2018108136A RU2754761C2 (ru) 2015-08-28 2016-08-26 Композиции, содержащие уролитины
SG10202001793PA SG10202001793PA (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
AU2016314987A AU2016314987B2 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
CN201680050456.6A CN108289879B (zh) 2015-08-28 2016-08-26 包含尿石素化合物的组合物
US15/757,293 US10695320B2 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
PCT/EP2016/070255 WO2017036992A1 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
MX2018002543A MX2018002543A (es) 2015-08-28 2016-08-26 Composiciones que comprenden compuestos de urolitina.
PT167572635T PT3340977T (pt) 2015-08-28 2016-08-26 Composições compreendendo compostos de urolitina
CA2996724A CA2996724C (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
HK18116292.1A HK1257500B (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
EP16757263.5A EP3340977B1 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
JP2018529732A JP7227003B2 (ja) 2015-08-28 2016-08-26 ウロリチン化合物を含む組成物
KR1020187007291A KR102660005B1 (ko) 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물
ES16757263T ES2936723T3 (es) 2015-08-28 2016-08-26 Composiciones que comprenden compuestos de urolitina
BR112018003745-1A BR112018003745B1 (pt) 2015-08-28 2016-08-26 Composições que compreendem um composto de urolitina e uso da referida composição
KR1020247012842A KR102822365B1 (ko) 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물
US16/901,182 US11337957B2 (en) 2015-08-28 2020-06-15 Compositions comprising urolithin compounds
US17/737,605 US11925616B2 (en) 2015-08-28 2022-05-05 Compositions comprising urolithin compounds
JP2022144671A JP2022177130A (ja) 2015-08-28 2022-09-12 ウロリチン化合物を含む組成物
US18/417,794 US20240148690A1 (en) 2015-08-28 2024-01-19 Compositions comprising urolithin compounds
JP2024174863A JP2025004129A (ja) 2015-08-28 2024-10-04 ウロリチン化合物を含む組成物
US19/310,137 US20260216125A1 (en) 2015-08-28 2025-08-26 Compositions comprising urolithin compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1515387.7A GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions

Publications (1)

Publication Number Publication Date
GB201515387D0 true GB201515387D0 (en) 2015-10-14

Family

ID=54326542

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1515387.7A Ceased GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions

Country Status (15)

Country Link
US (5) US10695320B2 (cg-RX-API-DMAC7.html)
EP (1) EP3340977B1 (cg-RX-API-DMAC7.html)
JP (3) JP7227003B2 (cg-RX-API-DMAC7.html)
KR (2) KR102660005B1 (cg-RX-API-DMAC7.html)
CN (1) CN108289879B (cg-RX-API-DMAC7.html)
AU (1) AU2016314987B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003745B1 (cg-RX-API-DMAC7.html)
CA (1) CA2996724C (cg-RX-API-DMAC7.html)
ES (1) ES2936723T3 (cg-RX-API-DMAC7.html)
GB (1) GB201515387D0 (cg-RX-API-DMAC7.html)
MX (1) MX2018002543A (cg-RX-API-DMAC7.html)
PT (1) PT3340977T (cg-RX-API-DMAC7.html)
RU (1) RU2754761C2 (cg-RX-API-DMAC7.html)
SG (1) SG10202001793PA (cg-RX-API-DMAC7.html)
WO (1) WO2017036992A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
PT2866804T (pt) 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
EP4553071A3 (en) * 2017-03-08 2025-07-23 Amazentis SA Methods for improving mitophagy in subjects
US20210267932A1 (en) 2018-05-15 2021-09-02 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods of using, and methods for preparing compounds
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
AU2021346837A1 (en) 2020-09-25 2023-03-02 Société des Produits Nestlé S. A. Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
JP7541673B2 (ja) * 2020-11-30 2024-08-29 国立研究開発法人産業技術総合研究所 筋ジストロフィーの抗炎症剤、筋ジストロフィーにおける抗炎症のための中心静脈栄養用組成物および筋ジストロフィーの抗炎症用食品組成物
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
US11820751B2 (en) 2021-01-27 2023-11-21 Vandria Sa Urolithin derivatives and methods of use thereof
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
JPWO2023199908A1 (cg-RX-API-DMAC7.html) * 2022-04-11 2023-10-19
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
WO2024142098A1 (en) * 2022-12-27 2024-07-04 Indian Institute Of Science A method for the treatment of epilepsy
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
EP4555997A1 (en) * 2023-11-15 2025-05-21 Science4Beauty Sp. z o.o. Water-soluble composition comprising urolithin
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
KR20250158913A (ko) 2024-04-30 2025-11-07 주식회사 파이안바이오테크놀로지 유로리틴을 함유하는 탈모완화제와 모발성장촉진제
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations
GB202416802D0 (en) 2024-11-14 2025-01-01 Amazentis Sa Urolithin combination

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 C型肝炎の予防・治療剤
JP2000507268A (ja) 1996-03-26 2000-06-13 イーライ・リリー・アンド・カンパニー ベンゾチオフェン類、それを含む製剤、および方法
WO1999053941A1 (fr) * 1998-04-15 1999-10-28 Shionogi & Co., Ltd. Preparations orales contenant des derives de trh
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US20050282781A1 (en) * 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
JP5147239B2 (ja) 2004-09-29 2013-02-20 三栄源エフ・エフ・アイ株式会社 コエンザイムq10含有乳化組成物
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP2145904A1 (de) 2008-07-18 2010-01-20 Basf Se Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
CN104016951B (zh) 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
PL2550092T3 (pl) 2010-03-22 2019-01-31 Instillo Gmbh Sposób wytwarzania mikro- lub nanocząstek
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
JP2013544829A (ja) 2010-11-24 2013-12-19 エクセリクシス, インク. PI3K/mTORの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法
JP2012111712A (ja) 2010-11-25 2012-06-14 Toyo Capsule Kk 油性ビタミンc経口投与用組成物
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
US20140079729A1 (en) * 2012-09-14 2014-03-20 Natreon, Inc. Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit
GB201323008D0 (en) * 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions

Also Published As

Publication number Publication date
JP7227003B2 (ja) 2023-02-21
US11925616B2 (en) 2024-03-12
RU2018108136A (ru) 2019-09-30
US11337957B2 (en) 2022-05-24
US20180243261A1 (en) 2018-08-30
KR20180037052A (ko) 2018-04-10
JP2018533618A (ja) 2018-11-15
US10695320B2 (en) 2020-06-30
BR112018003745B1 (pt) 2023-11-07
MX2018002543A (es) 2018-06-15
AU2016314987B2 (en) 2021-07-08
RU2018108136A3 (cg-RX-API-DMAC7.html) 2020-01-31
US20220323407A1 (en) 2022-10-13
CN108289879B (zh) 2026-05-26
US20200323818A1 (en) 2020-10-15
JP2025004129A (ja) 2025-01-14
AU2016314987A1 (en) 2018-03-29
KR102660005B1 (ko) 2024-04-22
CN108289879A (zh) 2018-07-17
CA2996724C (en) 2024-05-21
SG10202001793PA (en) 2020-04-29
EP3340977B1 (en) 2022-11-02
RU2754761C2 (ru) 2021-09-07
ES2936723T3 (es) 2023-03-21
CA2996724A1 (en) 2017-03-09
HK1257500A1 (en) 2019-10-25
WO2017036992A1 (en) 2017-03-09
BR112018003745A2 (pt) 2018-09-25
US20240148690A1 (en) 2024-05-09
US20260216125A1 (en) 2026-07-30
PT3340977T (pt) 2023-01-31
KR102822365B1 (ko) 2025-06-17
KR20240060826A (ko) 2024-05-08
JP2022177130A (ja) 2022-11-30
EP3340977A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
IL261792B (en) Preparations
IL260933A (en) Preparations containing tocorsol or its analogues
SG11201705415YA (en) Multi-supplement compositions
IL257131A (en) Preparations
GB201610156D0 (en) Cliptac compositions
SG10202001793PA (en) Compositions comprising urolithin compounds
GB201501598D0 (en) Compositions
IL256559B1 (en) Flinbolin preparations
GB201506827D0 (en) Composition
GB201505527D0 (en) Composition
GB201515391D0 (en) Compositions
GB201506830D0 (en) Composition
GB201506825D0 (en) Composition
GB201506829D0 (en) Composition
GB201504665D0 (en) Composition
SI3349766T1 (sl) Antihemoragični sestavki
GB201504307D0 (en) Composition
GB201622161D0 (en) Compositions
GB201614799D0 (en) Compositions
GB201506828D0 (en) Composition
GB201505520D0 (en) Composition
GB2538335B (en) Compositions
GB201508722D0 (en) Composition
GB201506826D0 (en) Composition
GB201602658D0 (en) Compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)